TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00806195

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197
Description: Four 0.5mL vaccinations of MenACWY-CRM197 conjugate vaccine was administered by intramuscular injection at 2, 4, 6 and 12 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197
Description: Four 0.5mL vaccinations of MenACWY-CRM197 conjugate vaccine was administered by intramuscular injection at 2, 4, 6 and 12 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197
Description: Four 0.5mL vaccinations of MenACWY-CRM197 conjugate vaccine was administered by intramuscular injection at 2, 4, 6 and 12 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP (Diptheria, Tetanus, Pertussis) Vaccine
Description: Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP (Diptheria, Tetanus, Pertussis) Vaccine
Description: Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP (Diptheria, Tetanus, Pertussis) Vaccine
Description: Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP (Diptheria, Tetanus, Pertussis) Vaccine
Description: Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP (Diptheria, Tetanus, Pertussis) Vaccine
Description: Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP (Diptheria, Tetanus, Pertussis) Vaccine
Description: Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib (Haemophilus influenza b) Vaccine
Description: Four vaccinations of Hib (Haemophilus influenza b) vaccine was administered at 2, 4, 6 and 15 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib (Haemophilus influenza b) Vaccine
Description: Four vaccinations of Hib (Haemophilus influenza b) vaccine was administered at 2, 4, 6 and 15 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib (Haemophilus influenza b) Vaccine
Description: Four vaccinations of Hib (Haemophilus influenza b) vaccine was administered at 2, 4, 6 and 15 months of age.
Study: NCT02426021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202 Placebo
Description: Subcutaneous administration of MLN1202 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202 Placebo
Description: Subcutaneous administration of MLN1202 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202 Placebo
Description: Subcutaneous administration of MLN1202 placebo
Study: NCT01767454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib 100 mg or 150 mg BID orally will be administered. Capsules with unit dose strengths of 50 mg or 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib 100 mg or 150 mg BID orally will be administered. Capsules with unit dose strengths of 50 mg or 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 1 mg or 2 mg once daily will be administered. Tablets with unit dose strengths of 0.5 mg or 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg intravenously over 90 minutes Q3W for a total of 4 doses will be administered. Supplied as Vials of 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg intravenously over 90 minutes Q3W for a total of 4 doses will be administered. Supplied as Vials of 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL)
Study: NCT02751593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone 40mg/d for 4 days
Study: NCT04223843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium + olodaterol
Description: Oral Inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Inhalation
Study: NCT01186120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biolimus A9-eluting stent
Description: drug-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent
Description: drug-eluting stent
Study: NCT01978782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram
Study: NCT00105716

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone behavioral education

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computer behavioral education
Study: NCT00006151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: Weekly behavioral therapy based on Project Match Motivational Therapy clinical manual plus systematic cigarette tapering.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Therapy
Description: Weekly behavioral therapy based on Project Match Motivational Therapy clinical manual plus systematic cigarette tapering.
Study: NCT00018655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twelve Step Facilitation
Description: Twelve Step Facilitation Therapy involves focusing on topics from 12-Step programs which support sobriety goals and personal growth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Treatment
Description: Integrated Cognitive Behavioral Treatment involves focusing on thoughts, activities, and interactions with people related to depressive symptoms and/or substance use.
Study: NCT04624464

Intervention type: OTHER
Intervention: Rectal swabs - microbiological analysis
Description: Microbial analyses will be performed from the rectal swabs obtained.

Intervention type: OTHER
Intervention: Rectal swabs - microbiological analysis
Description: Microbial analyses will be performed from the rectal swabs obtained.

Intervention type: OTHER
Intervention: Examination of patient room
Description: Only performed for cohort 2
Study: NCT03081442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine contraceptive device IUCD
Description: bimanual examination. The cervix was exposed by introducing a vaginal speculum, the cervix and vaginal vault were cleaned with povidone- iodine solution.~The Next step was to sound The IUD was folded into the insertion tube immediately prior to insertion. The cervix was grasped with a tenaculum, and gently pulled downward The insertion tube was advanced into the uterus to the correct depth as marked on the tube by a sliding plastic flange.~The outer sheath of the insert was withdrawn ashort distance to release the arms of the T and was then gently pushed inward again to elevate the opened T against the fundus of uterus .

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intrauterine contraceptive device IUCD
Description: bimanual examination. The cervix was exposed by introducing a vaginal speculum, the cervix and vaginal vault were cleaned with povidone- iodine solution.~The Next step was to sound The IUD was folded into the insertion tube immediately prior to insertion. The cervix was grasped with a tenaculum, and gently pulled downward The insertion tube was advanced into the uterus to the correct depth as marked on the tube by a sliding plastic flange.~The outer sheath of the insert was withdrawn ashort distance to release the arms of the T and was then gently pushed inward again to elevate the opened T against the fundus of uterus .
Study: NCT01077648

Intervention type: DRUG
Intervention: Trastuzumab or Lapatinib
Description: Anti-erbB2 therapy for breast cancer treatment will be analyzed as a class level variable; individual drugs including trastuzumab and lapatinib will also be explored as exposures if sufficient numbers of patients exist.
Study: NCT01704586

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radioiodine I-131
Description: Radioiodine will be used for ablation therapy, dosimetry and posttherapeutic whole body scan, as well as low dose I-131 imaging.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: I-124
Description: I-124 will be used for imaging to assess uptake inside and outside of thyroid bed, using PET/CT whole body scanning, followed by I-131 therapy as necessary as per protocol.
Study: NCT03677258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen for injections 7%
Description: Injection of medical device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid for injections 2%
Description: Injection of medical device
Study: NCT04620551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sub-clinical stimulation
Description: The third night of recording will involve sub-clinical thresholds of stimulation in all subjects.
Study: NCT02604316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arabinoxylan
Description: 10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beta- Glucan
Description: 10 days of weight loss diet calculated as 100% RMR + 6g β-glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
Study: NCT02968069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI
Description: Endoscopic factors under white light view and simplified narrow band imaging classification assisting in diagnosing cancerous lesions will be recorded.
Study: NCT02603770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XueZhiKang

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovastatin
Study: NCT04578860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy with Music Care app
Description: Listening to music with Music Care app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sound therapy with White Noise
Description: Listening to white noise with an app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual for sleep disorders
Description: No intervention
Study: NCT00365456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parathyroid Hormone (PTH)
Description: Self-administered (100 μg in a volume of 71.4 μL) daily as a subcutaneous injection in the abdomen using the Preotact pen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Orally once weekly as one 35 mg tablet.
Study: NCT01846728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen suppression
Description: Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function
Study: NCT01925573

Intervention type: DEVICE
Group type: OTHER
Intervention: Optune(NOVOTTF-100A)
Study: NCT03834467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1 - Elevation Stimulus Video
Description: Subjects will watch a video that has been shown in previous studies to elicit an elevation response. This video shows a news story about a man saving the life of another man who falls onto the subway tracks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Arm 2 - Control Stimulus Video
Description: Subjects will watch a nature video.
Study: NCT01659242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate plus sulfasalazine
Description: ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: ARM 2:Leflunomide(LEF)~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.~Methotrexate:Off
Study: NCT01835015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLG561
Description: Administered by intravitreal injection, Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLG561
Description: Administered by intravitreal injection, Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLG561
Description: Administered by intravitreal injection, Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLG561
Description: Administered by intravitreal injection, Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLG561
Description: Administered by intravitreal injection, Day 1
Study: NCT02520687

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: 200mls daily for seven days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-depleted beetroot juice
Description: 200mls daily for seven days
Study: NCT03060044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone Easyhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone Easyhaler with charcoal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus with charcoal
Study: NCT03011268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of anti-TNF treatment
Description: Discontinuation of treatment with Infliximab, Adalimumab, and Golimumab in order to record time to relapse occurrences

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of anti-TNF treatment
Description: Continuation of treatment with Infliximab, Adalimumab, and Golimumab for 2 years after randomization, then discontinue
Study: NCT01986920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101 25%
Description: Low Dose Concentration of A-101 applied to one of 4 Target Lesions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101 32.5%
Description: Mid Dose Concentration of A-101 applied to one of 4 Target Lesions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101 40%
Description: High Dose Concentration A-101 applied to one of 4 Target Lesions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A-101 Vehicle
Description: Placebo applied to one of 4 Target Lesions
Study: NCT02238704

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Regimen A calcium and iron/folic acid
Description: Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regimen B calcium and iron/folic acid
Description: Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
Study: NCT01540253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K inhibitor BKM120
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00441974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adefovir dipivoxil
Description: adefovir dipivoxil once daily one tablet 10mg orally
Study: NCT02263521

Intervention type: OTHER
Intervention: No intervention employed. Study is based on a cross-sectional observational design.

Intervention type: OTHER
Intervention: No intervention employed. Study is based on a cross-sectional observational design.

Intervention type: OTHER
Intervention: No intervention employed. Study is based on a cross-sectional observational design.
Study: NCT01966328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 36% Resolvine Intravitreal Injection
Description: 36% Resolvine Intravitreal Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 9% Resolvine Intravitreal Injection
Description: 9% Resolvine Intravitreal Injection
Study: NCT03172832

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTBD
Description: Percutaneous access and tube placement into the bile duct

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERC
Description: Endoscopic access and stent placement in the bile duct
Study: NCT04165226

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low level light therapy
Description: Patients will be offered 8 sessions of photobiomodulation using HPL Pagani Diode 808/915nm LLLT 3.2W (Fimad Elettromedicali SRL®, Catanzaro, Italy) with the parameters adjusted individually according to the surface area to be treated. Optimum dose is 10 joules/cubic centimeters. The patients will take 2 to3 sessions / week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2
Description: Patients will be offered 2 sessions of fractional carbon dioxide laser on a 4 weeks interval. Topical anesthesia with pridocaine cream will be applied under occlusion for 30 - 60 minutes before the session.~* Please update to the proper apparatus and parameters DEXA SmartXide DOT Fractional CO2 laser system 10600 nm (DEKA®, Florence, Italy) will be used with the following parameters adjusted individually to patients': power of 15-20 W, dwell time of 500-800 μs, spacing of 200-500 μm, and stack 2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combined fractional CO2 laser and low level light therapy
Description: Combined treatment of both modalities (fractionational CO2 laser and low level light therapy). Please describe more....
Study: NCT00988143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2009-2010 Trivalent Influenza Virus Vaccine
Description: 0.25 mL, Intramuscular (participants at 6 to 35 months of age - Pediatric Dose); Others 0.5 mL, Intramuscular.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2008-2009 Trivalent Influenza Virus Vaccine
Description: 0.25 mL, Intramuscular; 0.5 mL, Intramuscular.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Influenza Virus Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT01661855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole
Description: 50mg once daily (QD) for 12 weeks for participants 6-11 years old; 50mg twice daily (BID) for 12 weeks for participants 12-17 years old

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator once daily (QD) for 12 weeks for participants 6-11 years old; Placebo comparator twice daily (BID) for 12 weeks for participants 12-17 years old
Study: NCT03889275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5395
Description: Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5395
Description: Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5395
Description: Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5395
Description: Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5395
Description: Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5395
Description: Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5395
Description: Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5395
Description: Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.
Study: NCT00304200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide and SU11248
Description: First Cohort: Temozolomide 100 mg/m2 orally week 1 and week 3 of a 28-day cycle; SU11248, 25 mg/day orally on weeks 2, 3, and 4 or a 28 day cycle.